AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 35971596
Drug: AZD9977 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD9977 100 mg once daily for 14 days, up-titrated to 200 mg for another 14 days
Trial: 35971596
Drug: Spironolactone 25
RxNorm normalized name: spironolactone 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spironolactone 25 mg once daily for 14 days, up-titrated to 50 mg for another 14 days
Trial: 34886680
Drug: Aspirin 325
RxNorm normalized name: aspirin 325 MG
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin 325 mg once daily
Trial: 32272243
Drug: Budesonide Oral
RxNorm normalized name: budesonide Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide Oral Suspension (BOS) 2.0 mg twice daily for 12 weeks
Trial: 35692186
Drug: Tetrahydrocannabinol (dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetrahydrocannabinol (dose = 13‐49 mg)
Trial: 36713761
Drug: Rivaroxaban monotherapy
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rivaroxaban monotherapy
Trial: 35704345
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with rivaroxaban and antiplatelet therapy
Trial: 33279874
Drug: Erlotinib plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib plus bevacizumab (15 mg/kg every 21 days)
Trial: 33279874
Drug: Erlotinib monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib monotherapy (150 mg once daily)
Trial: 36054477
Drug: Preoperative NSAIDs
RxNorm normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative NSAIDs (administered from 24 hours pre-surgery to day 7 post-surgery)
Trial: 36054477
Drug: Postoperative NSAIDs
RxNorm normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative NSAIDs (administered from 12 hours post-surgery to day 7 post-surgery)
Trial: 35710394
Drug: Inpatient treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inpatient treatment as usual
Trial: 35710394
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (Stepped care day patient approach and Inpatient treatment as usual)
Trial: 33223005
Drug: 0.75 mg.kg‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.75 mg.kg‐1 flurbiprofen axetil (Group C)
Trial: 33223005
Drug: 1 mg.kg‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg.kg‐1 flurbiprofen axetil (Group D)
Trial: 33223005
Drug: 10 mL
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mL of Intralipid (Group A, control group)
Trial: 33223005
Drug: 0.5 mg.kg‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg.kg‐1 flurbiprofen axetil (Group B)
Trial: 32141787
Drug: IncobotulinumtoxinA 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IncobotulinumtoxinA 400 U injection in J-PURE (upper limb)
Trial: 32141787
Drug: IncobotulinumtoxinA 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IncobotulinumtoxinA 400 U injection in J-PLUS (lower limb)
Trial: 35229691
Drug: Convalescent plasma
RxNorm normalized name: Convalescent plasma
DrugBank: COVID-19 convalescent plasma (DB15692)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Convalescent plasma added to conventional therapy
Trial: 32241351
Drug: Low-level laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-level laser therapy (LLLT) applied every 4 weeks for 12 weeks
Trial: 34036828
Drug: Systematic visual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systematic visual oral examinations for screening
Trial: 34036828
Drug: Use of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of primary health care workers for oral cancer screening
Trial: 32470370
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg Diclofenac Potassium (DFK)
Trial: 32248163
Drug: Common treatment
RxNorm normalized name: Common carp
DrugBank: Common carp (DB10614)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Common treatment scheme (control group)
Trial: 32551724
Drug: Both therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both therapies (DET and CPT)
Trial: 33926539
Drug: Radiofrequency ablation
RxNorm normalized name: phenylephrine hydrochloride Ophthalmic Solution [AK-Dilate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiofrequency ablation (RFA) followed by chemotherapy
Trial: 34460897
Drug: 12-week outpatient
RxNorm normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12-week outpatient physical therapy program with progressive resistance training (PRT)
Trial: 34460897
Drug: 6-week outpatient
RxNorm normalized name: perampanel
DrugBank: Perampanel (DB08883)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 6-week outpatient physical therapy program with progressive resistance training (PRT)
Trial: 32532789
Drug: Nivolumab 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab 3 mg/kg once every 2 weeks until disease progression or unacceptable toxicity
Trial: 32131366
Drug: Group A
RxNorm normalized name: Blood group A IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A received a sachet containing 5 g CPs, 3.6 g calcium lactate (equivalent to 500 mg of elemental calcium) and 400 IU vitamin D3
Trial: 32131366
Drug: Group B
RxNorm normalized name: Blood group B IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B received a chewable tablet containing 1.25 g calcium carbonate (equivalent to 500 mg of elemental calcium) and 400 IU vitamin D3 daily
Trial: 32764898
Drug: FNB (femoral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FNB (femoral nerve block) with 15 mL of 0.5% ropivacaine
Trial: 32764898
Drug: FICB (fascia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FICB (fascia iliaca compartment block) with 40 mL of 0.5% ropivacaine
Trial: 36385193
Drug: Calcifediol (HyD,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcifediol (HyD, 20 mcg/d)
Trial: 33433351
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation of perindopril tert-butylamine tablets (4 mg)
Trial: 34263280
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg of daidzein with 10 g soy protein
Trial: 34263280
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg of genistein with 10 g soy protein
Trial: 34263280
Drug: 0 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 mg of daidzein and genistein with 10 g soy protein (placebo group)
Trial: 35247994
Drug: Standard oncological
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard oncological treatments (checkpoint inhibitors, checkpoint inhibitors combined with chemotherapy or oncological surveillance)
Trial: 33625743
Drug: Biodegradable implants
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Biodegradable implants
Trial: 32666354
Drug: Desvenlafaxine succinate
RxNorm normalized name: Desvenlafaxine Succinate
DrugBank: Desvenlafaxine (DB06700)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Desvenlafaxine succinate monohydrate extended release tablets
Trial: 32666354
Drug: In vitro
RxNorm normalized name: glucuronidase in vitro test
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In vitro dissolution tests using USP apparatus 1 at 75 rpm with HCl pH 1.2, acetate buffer solution pH 4.5, or phosphate buffer solution pH 6.8
Trial: 34406788
Drug: Conidial suspension
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conidial suspension (1 × 10^6 conidia/ml) inoculation on three leaves of three plants
Trial: 32794449
Drug: Online imaginal
RxNorm normalized name: triclosan
DrugBank: Triclosan (DB08604)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Online imaginal exposure therapy for EDs (4 sessions over 4 weeks)
Trial: 35851045
Drug: Budesonide/formoterol 200/6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide/formoterol 200/6 μg via turbuhaler
Trial: 35851045
Drug: Salbutamol 100
RxNorm normalized name: Salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Salbutamol 100 μg via MDI
Trial: 36137682
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care (vitamin K antagonists or antiplatelet therapy)
Trial: 36137682
Drug: Apixaban vs
RxNorm normalized name: Apixaban
DrugBank: Apixaban (DB06605)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Apixaban vs antiplatelet therapy
Trial: 36137682
Drug: Apixaban vs
RxNorm normalized name: Apixaban
DrugBank: Apixaban (DB06605)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Apixaban vs vitamin K antagonists
Trial: 34217889
Drug: Cognitive-behavioral therapy-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy-based pain coping skills training with optional opioid taper support (18 telephone sessions over 52 weeks)
Trial: 34217889
Drug: Cognitive-behavioral therapy-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy-based pain coping skills training with optional opioid taper support
Trial: 34842343
Drug: Omega 3
RxNorm normalized name: omega 3,6
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Omega 3 fatty acids 1000 mg/day for 6 months
Trial: 35568494
Drug: COT (Conventional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COT (Conventional Occupational Therapy)
Trial: 35568494
Drug: COT+CCH (Conventional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COT+CCH (Conventional Occupational Therapy + Chinese Calligraphy Handwriting)
Trial: 35568494
Drug: COT+GRASP (Conventional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COT+GRASP (Conventional Occupational Therapy + Graded Repetitive Arm Supplementary Program)
Trial: 33345396
Drug: Chemotherapy (docetaxel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (docetaxel or paclitaxel)
Trial: 32794176
Drug: Transnasal Humidified
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transnasal Humidified Rapid‐Insufflation Ventilatory Exchange (THRIVE) with 100% oxygen at 70 l min−1 during apnoea
Trial: 32738099
Drug: Dinaciclib (6-12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dinaciclib (6-12 mg/m2 i.v.) and MK-2206 (60-135 mg p.o.) weekly
Trial: 32738099
Drug: Dinaciclib (9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dinaciclib (9 mg/m2) and MK-2206 (135 mg) at recommended dose
Trial: 32738099
Drug: Dinaciclib and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dinaciclib and MK-2206 combination
Trial: 35144911
Drug: Drug trials
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug trials in GP practices
Trial: 36006207
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin type A (BoNT‐A) injection (50 U)
Trial: 32666576
Drug: Multi-professional medication
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-professional medication review (MPMR) service
Trial: 35132024
Drug: Gabapentin enacarbil
RxNorm normalized name: Gabapentin Enacarbil
DrugBank: Gabapentin enacarbil (DB08872)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gabapentin enacarbil 600 mg twice daily starting the day before surgery continuing for 3 days thereafter
Trial: 32841256
Drug: Micronutrient supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micronutrient supplement
Trial: 34591227
Drug: IRLA with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IRLA with heated lidocaine gel (20 mL 2% lidocaine gel at 40 ℃)
Trial: 34591227
Drug: IRLA with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IRLA with room temperature lidocaine gel (20 mL 2% lidocaine gel)
Trial: 32265417
Drug: ANG-3777 (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ANG-3777 (2 mg/kg, 3 once-daily IV infusions)
Trial: 32282539
Drug: Prescribing biologics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescribing biologics over immunosuppressants based on risk factors
Trial: 32282539
Drug: Endoscopy-driven treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endoscopy-driven treatment in long-standing disease after failure of thiopurines
Trial: 32282539
Drug: Endoscopy-driven treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endoscopy-driven treatment in elderly patients
Trial: 35273223
Drug: Newly designed
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Newly designed patch fabricated by blending poly(L-lactic acid) and poly(ε-caprolactone) exposed to amniotic fluid for 16 weeks
Trial: 35273223
Drug: Newly designed
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Newly designed patch fabricated by blending poly(L-lactic acid) and poly(ε-caprolactone) exposed to phosphate-buffered saline (PBS) for 16 weeks
Trial: 34535165
Drug: Hydroxychloroquine (HCQ)
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine (HCQ) at a dose of 400 mg/daily for 8 weeks
Trial: 33208014
Drug: Anti‐CCP therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti‐CCP therapy (negative control group)
Trial: 35332737
Drug: Treatment group
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment group 1
Trial: 35332737
Drug: Treatment group
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment group 2
Trial: 36281151
Drug: TXA +
RxNorm normalized name: Tranexamic acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TXA + DEXA (15 mg/kg TXA before skin incision and 3 hours later; 20 mg dexamethasone intravenously after the onset of anesthesia, and again 24 hours later)
Trial: 34237755
Drug: Behavioral and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral and pelvic floor muscle therapy combined with midurethral sling
Trial: 39246931
Drug: Placebo (vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (vehicle solution)
Trial: 35028615
Drug: PXL770 500
RxNorm normalized name: PXL770 free acid anhydrous
DrugBank: PXL-770 free acid anhydrous (DB17615)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PXL770 500 mg QD
Trial: 33236706
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment with dual antiparasitic therapy and corticosteroids
Trial: 32877425
Drug: Cognitive behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioral therapy journal app (active control)
Trial: 35387431
Drug: Energy Drink
RxNorm normalized name: Boost Energy Drink
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Energy Drink (3 mg caffeine per kg of body weight)
Trial: 33892764
Drug: Constraint-induced Aphasia
RxNorm normalized name: constant albicans extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Constraint-induced Aphasia Therapy Plus (CIAT Plus)
Trial: 33892764
Drug: Multi-modality Aphasia
RxNorm normalized name: Parasedge Multi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-modality Aphasia Therapy (M-MAT)
Trial: 32569239
Drug: Half dose
RxNorm normalized name: propranolol hydrochloride Extended Release Oral Capsule [Half-Betadur CR]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Half dose of low‐molecular‐weight heparin sodium injection (FLUXUM)
Trial: 32569239
Drug: Full dose
RxNorm normalized name: BayRHo-D Full Dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full dose of low‐molecular‐weight heparin sodium injection (FLUXUM)
Trial: 32569239
Drug: Argatroban injection
RxNorm normalized name: argatroban Injection
DrugBank: Argatroban (DB00278)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Argatroban injection
Trial: 37452140
Drug: Etoricoxib 90
RxNorm normalized name: etoricoxib 90 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etoricoxib 90 mg
Trial: 34851729
Drug: 75 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 μg fentanyl
Trial: 35644684
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of iodine intake and excretion increments
Trial: 33506195
Drug: Oral sedation
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral sedation (lorazepam 1 mg/oxycodone 5 mg)
Trial: 34874654
Drug: Cytoflavin tablets,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytoflavin tablets, 2 tablets 2 times a day for 25 days
Trial: 34874654
Drug: Other drugs
RxNorm normalized name: Other drugs for bile therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other drugs (vitamins, nootropic drugs)
Trial: 36374982
Drug: Cordyceps cicadae
RxNorm normalized name: Cicada periostracum extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cordyceps cicadae mycelium supplementation (1,050 mg daily for 90 days)
Trial: 32661006
Drug: Interferon β‐1a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon β‐1a (IFN β‐1a) administered at a dose of 44-μg/ml (12 million IU/ml) subcutaneously injected three times weekly for two consecutive weeks, in addition to national protocol medications (hydroxychloroquine plus lopinavir-ritonavir or atazanavir-ritonavir)
Trial: 32661006
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group received only national protocol medications (hydroxychloroquine plus lopinavir-ritonavir or atazanavir-ritonavir)
Trial: 32390248
Drug: Tolperisone (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolperisone (150 mg TID)
Trial: 32390248
Drug: Cyclobenzaprine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclobenzaprine (10 mg TID)
Trial: 33078467
Drug: Cognitive Processing
RxNorm normalized name: Allogeneic processed thymus tissue
DrugBank: Allogeneic processed thymus tissue (DB16736)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Processing Therapy (CPT) - Group format
Trial: 33078467
Drug: Cognitive Processing
RxNorm normalized name: Allogeneic processed thymus tissue
DrugBank: Allogeneic processed thymus tissue (DB16736)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Processing Therapy (CPT) - Individual format
Trial: 33078467
Drug: Cognitive Processing
RxNorm normalized name: Allogeneic processed thymus tissue
DrugBank: Allogeneic processed thymus tissue (DB16736)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Processing Therapy (CPT) - Both formats (Group and Individual)
Trial: 35694708
Drug: Self-made Hewei
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-made Hewei decoction plus conventional western medicine
Trial: 34301974
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg escitalopram for 7 days
Trial: 35644305
Drug: GDC-4379 10
RxNorm normalized name: calcium carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GDC-4379 10 mg QD
Trial: 35644305
Drug: GDC-4379 30
RxNorm normalized name: calcium carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GDC-4379 30 mg QD
Trial: 35644305
Drug: GDC-4379 40
RxNorm normalized name: calcium carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GDC-4379 40 mg BID
Trial: 35644305
Drug: GDC-4379 80
RxNorm normalized name: calcium carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GDC-4379 80 mg QD
Trial: 36899369
Drug: Amlodipine 5
RxNorm normalized name: amlodipine 5 MG
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amlodipine 5 mg once daily
Trial: 34304419
Drug: MR and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MR and JVE‐L combined vaccination group (experimental group)
Trial: 36382660
Drug: Oral counseling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral counseling
Trial: 32651768
Drug: Racemic epinephrine
RxNorm normalized name: EPINEPHRINE,RACEMIC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Racemic epinephrine (RE) nebulization, 0.2 ml of RE added to 1.8 ml of distilled water, re-administered if needed on 6 h.
Trial: 32651768
Drug: 3% hypertonic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3% hypertonic saline (HS) nebulization, 2 ml of 3% HS nebulized, frequency of 1 to 4 h.
Trial: 33704494
Drug: Lipid-based nutrient
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid-based nutrient supplements (LNSs)
Trial: 33075621
Drug: rice with
RxNorm normalized name: Rice
DrugBank: Rice (DB10563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rice with sugar solution (PSS + R)
Trial: 39304237
Drug: Oral ferrous
RxNorm normalized name: ferrous fumarate Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ferrous sulphate
Trial: 36271471
Drug: TransCon PTH
RxNorm normalized name: TransCon PTH
DrugBank: Palopegteriparatide (DB18676)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TransCon PTH (18 μg/d)